Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Strive Acquires Semler Scientific, Becomes 11th Largest Corporate Bitcoin Holder

Strive, Inc. has just completed the acquisition of Semler Scientific, making it the 11th largest public corporate holder of Bitcoin globally with approximately 12,797.9 bitcoins in its treasury. Additionally, the company has appointed Avik Roy as its Chief Strategy Officer, whose initial focus will be on expanding Semler Scientific's mandate in early disease detection products.

Since launching its first ETF in August 2022, Strive Asset Management, LLC, a direct, wholly owned subsidiary of Strive, has grown to manage over $2 billion in assets.

Semler Scientific, Inc., the acquired company, is the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and is a leader in medical devices and software to combat chronic diseases. Its flagship product, Quantaflo, provides rapid point-of-care testing to measure arterial blood flow in the extremities and aids in the diagnosis of peripheral arterial disease.

As part of the acquisition, Eric Semler, the former chairman and executive chairman of Semler Scientific, has joined Strive as an independent board member. Furthermore, Joe Burnett, previously the director of Bitcoin strategy for Semler Scientific, has joined Strive as the VP of Bitcoin strategy.

These developments mark a significant shift for Strive, as it further solidifies its position as a major player in the Bitcoin treasury space and expands its business into the early disease detection products market. Today the company's shares have moved -2.31% to a price of $0.9481. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS